Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 2 de 2
Filter
Add more filters










Database
Language
Publication year range
1.
Curr Oncol ; 23(3): 171-7, 2016 Jun.
Article in English | MEDLINE | ID: mdl-27330345

ABSTRACT

BACKGROUND: Despite lack of a true comparative study, the folfox (5-fluorouracil-leucovorin-oxaliplatin) and capox (capecitabine-oxaliplatin) regimens are believed to be similar in their efficacy and tolerability in the treatment of stage iii colorectal cancer. However, that belief has been disputed, because real-life data suggest that the capox regimen is more toxic, leading to more frequent reductions in the delivered dose intensity-thus raising questions about the effect of dose intensity on clinical outcomes. METHODS: A retrospective data review for two Canadian institutions, the Segal Cancer Centre and the Tom Baker Cancer Centre, considered patients diagnosed with stage iii colorectal cancer during 2006-2013. Primary endpoints were dose intensity and toxicity, with a secondary endpoint of disease-free survival. RESULTS: The study enrolled 180 eligible patients (80 at the Segal Cancer Centre, 100 at the Tom Baker Cancer Centre). Of those 180 patients, 75 received capox, and 105 received mfolfox6. In the capox group, a significant dose reduction was identified for capecitabine compared with 5-fluorouracil in mfolfox6 group (p = 0.0014). Similarly, a significant dose reduction was observed for oxaliplatin in mfolfox6 compared with oxaliplatin in capox (p = 0.0001). Compared with the patients receiving capox, those receiving mfolfox6 were twice as likely to experience a treatment delay of more than 1 cycle-length (p = 0.03855). Toxicity was more frequent in patients receiving mfolfox6 (nausea: 30% vs. 18%; diarrhea: 47% vs. 24%; peripheral sensory neuropathy: 32% vs. 3%). At a median follow-up of 40 months, preliminary data showed no difference in disease-free survival (p = 0.598). Pooled data from both institutions were also separately analyzed, and no significant differences were found. CONCLUSIONS: Our results support the use of capox despite a lack of head-to-head randomized trial data.

2.
Behav Neurosci ; 117(5): 1086-95, 2003 Oct.
Article in English | MEDLINE | ID: mdl-14570557

ABSTRACT

Euglandina rosea, a predatory land snail, tracks prey and mates by following slime trails. Euglandina follow slime trails more than 80% of the time, following trails of their own species, but not those of prey snails, in the direction that they were laid. The attractive elements of prey slime are small, water-soluble compounds detected by specialized lip extensions. Although olfaction plays no role in trail following, strong odors disrupt tracking. Inhibition of nitric oxide synthase also disrupts slime trail following, suggesting a role for nitric oxide in neural processing of slime trail stimuli. Euglandina can be conditioned to follow novel trails of glutamate or arginine paired with feeding on prey snails. These experiments demonstrate that slime-trail tracking in Euglandina is a robust, easily measured behavior that makes a good model system for studying sensory processing and learning in a novel modality.


Subject(s)
Feeding Behavior/physiology , Predatory Behavior/physiology , Snails/physiology , Animals , Helix, Snails/physiology , Odorants , Pheromones/physiology , Smell/physiology
SELECTION OF CITATIONS
SEARCH DETAIL
...